Articles tagged "Cytomeglovirus"

2017 American Transplant Congress
ASP0113 Elicits an Immune Response in CMV-Seronegative Dialysis Patients: Comparison to Healthy Subjects.
P. Bonate,¹ C. Van Sant,² K. Cho,¹ E. Zook,¹ L. Smith,³ S. Boutsaboualoy, X. Wang,¹ R. Wu,¹ A. Koester,⁴ D. Rammelsberg,⁶ R. Goldwater,⁴ T. Marbury.⁵
¹Astellas Pharma Global Development, Northbrook; ²Astellas Research Institute of America, Skokie; ³Vical Inc, San Diego; ⁴PAREXEL International, Baltimore; ⁵Orlando Clinical Research Center, Orlando; ⁶Randstad Pharma, Deerfield, IL, United States (on assignment at Astellas Pharma Global Development, Northbrook, United States)
Introduction: ASP0113 is a first-in-class, DNA-based vaccine in development for the prevention of CMV infection in at-risk hematopoietic cell transplant.Methods: A Phase 1, single-blind, parallel-group,…
2017 American Transplant Congress
Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients.
C. Payne,¹ J. Melaragno,¹ D. Hutchinson,¹ T. Babu,² P. Prasad,^2,3 T. Dick.¹
¹Pharmacy, University of Rochester Medical Center, Rochester, NY; ²Division of Infectious Diseases, University of Rochester Medical Center, Rochester, NY; ³Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY
BACKGROUND: Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can…
2017 American Transplant Congress
CMV-Infected Kidney Grafts Drive the Expansion of Blood-Born CMV-Specific T-Cells Restricted by Shared HLA Molecules Through Presentation on Donor's Cells.
P. Gatault,^1,2 S. Al-Hajj,¹ J. Noble,^1,2 E. Chevallier,^1,2 M. Piollet,¹ C. Forconi,¹ R. Lemoine,¹ J.-M. Halimi,^1,2 M. Büchler,^1,2 C. Baron.^1,2
¹EA 4245, François-Rabelais University, Tours, France; ²Kidney Transplantation Department, CHRU, Tours, France
Background. Cytomegalovirus specific immune response is crucial to control CMV infection in kidney transplant recipients (KTR), in whom recipient CMV can reactivated (R+) and donor…
2017 American Transplant Congress
Evaluation of Immunological States of Patients with Cytomegalovirus Infection After Kidney Transplantation.
A. Tanaka, K. Ide, Y. Tanaka, K. Ishiyama, M. Ohira, H. Tahara, S. Shimizu, D. Kumar, H. Ohdan.
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
Background: Generally, it is thought that strong immunosuppression causes cytomegalovirus (CMV) infection after kidney transplantation (KT); thus, physicians often reduce the dose of the immunosuppressant…
2017 American Transplant Congress
In the Modern Era, Cytomegalovirus Does Not Appear to Increase Intimal Thickening After Heart Transplantation.
D. Leong, B. Azarbal, J. Patel, M. Kittleson, L. Czer, T. Aintablian, D. Chang, D. Geft, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles
Background: Cytomegalovirus (CMV) has been associated with the subsequent development of cardiac allograft vasculopathy (CAV) after heart transplantation. In the more recent era, CMV has…
2017 American Transplant Congress
Acute Mouse CMV Infection Abrogates Transplant Tolerance by Modulating Myeloid Cell Differentiation and Function: A Possible Role for Transcription Factor RORγt.
A. Dangi,¹ L. Zhang,¹ X. Zhang,^2,3 Z. Zhang,^2,3 X. Luo.^1,2,3
¹Nephrology and Hypertension, Northwestern University, Chicago, IL; ²Comprehensive Transplant Center, Northwestern University, Chicago, IL; ³Comprehensive Transplant Center, Northwestern University, Chicago, IL
Cytomegalovirus (CMV) infection has long been associated with graft-dysfunction and rejection in transplant-recipients. Nevertheless, precise understanding of underlying molecular mechanisms remains unclear. Here, we investigated…
2017 American Transplant Congress
Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.
S. El Hajj, M. Kim, J. Azzi, S. Gabardi.
Kidney Transplant, Brigham and Women's Hostpial, Boston, MA
Introduction: Cytomegalovirus (CMV) remains one the most clinically relevant and frequent post-transplant infections. Despite the availability of effective antiviral drugs, CMV continues to be of…
2017 American Transplant Congress
Reducing the Early Readmission Rates in Kidney Transplantation.
M. Tavares, M. Cristelli, L. Viana, I. Malbouisson, M. Paula, H. Silva Junior, J. Pestana.
Nephrology Division, Hospital do Rim Foudation, São Paulo, Brazil
Background: 30-day hospital readmission rate is a well-accepted quality metric and a predictor of mortality among kidney transplant recipients.Objective: The aim of this study is…
2017 American Transplant Congress
IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).
S. Ge, B.-H. Shin, J. Mirocha, D. Thomas, M. Chu, E. Rodriguez, C. Chao, A. Petrosyan, O. Galera, A. Vo, J. Choi, A. Peng, J. Kahwaji, S. Jordan, M. Toyoda.
Transplant Immunology Laboratory, Biostatistics Core and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Background: VIs represent significant morbidity factors in KTx pts. DES followed by KTx with ATZ induction increased successful Tx rates in HS pts, but may…
2017 American Transplant Congress
Cytomegalovirus Viral Load: Characterization of Results from Clinical Specimens.
S. Kleiboeker.
Viracor Eurofins, Lees Summit, MO
Cytomegalovirus (CMV) infection, a frequent complication affecting solid organ and hematopoietic stem cell transplant recipients, is commonly diagnosed and monitored by quantitative PCR (qPCR) methods.…